Emil Kakkis, Ultragenyx CEO

Ul­tragenyx nears $50M Se­ries A for its Alzheimer's gene ther­a­py spin­out: #JPM24

SAN FRAN­CIS­CO — Ul­tragenyx, the com­mer­cial-stage Cal­i­for­nia biotech work­ing on ul­tra-rare dis­eases, is fin­ish­ing up a $50 mil­lion Se­ries A fundraise for its Alzheimer’s gene ther­a­py spin­out, named Am­logenyx, CEO Emil Kakkis told End­points News. 

“We have a lead in­vestor signed on, and we have sev­er­al in­vestors who are on board. We’re still try­ing to fill out a $50 mil­lion syn­di­cate,” Kakkis said on the side­lines of this year’s JP Mor­gan Health­care Con­fer­ence on Mon­day. “We have most of it, or a good part of it, so we’re try­ing to get the last two, three peo­ple to fin­ish it.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.